Bradykinin
- Generic Name
- Bradykinin
- Drug Type
- Small Molecule
- Chemical Formula
- C50H73N15O11
- CAS Number
- 58-82-2
- Unique Ingredient Identifier
- S8TIM42R2W
- Background
Bradykinin has been investigated for the basic science and treatment of Hypertension and Diabetes Type 2.
Pharvaris Expands Deucrictibant Development to Acquired Angioedema Following Promising Early Data
Pharvaris announces plans to initiate a clinical trial for deucrictibant in acquired angioedema, expanding beyond its ongoing Phase 3 trials in hereditary angioedema. The decision follows encouraging results in three patients, as the company advances its bradykinin B2 receptor antagonist program with both immediate and extended-release formulations.
Astria Therapeutics Advances Navenibart for HAE with Phase 3 Trial
• Astria Therapeutics is initiating the ALPHA-ORBIT Phase 3 trial to evaluate navenibart for hereditary angioedema (HAE) with flexible dosing.
• The trial will assess the efficacy and safety of navenibart administered every 3 or 6 months over a 6-month period in HAE patients.
• Positive Phase 1b/2 results showed a 90-95% reduction in mean monthly attack rate and up to 67% attack-free rate with navenibart.
• ALPHA-ORBIT's design incorporates feedback from regulators and aims for global registration, potentially making navenibart a first-choice HAE therapy.
CSL's Andembry (Garadacimab) Approved in Europe and UK for Hereditary Angioedema
• The European Commission and the MHRA have approved CSL's Andembry (garadacimab) for preventing hereditary angioedema (HAE) attacks in patients aged 12 and older.
• Andembry, a Factor XIIa-inhibitory monoclonal antibody, offers a novel approach by targeting the initiation of the angioedema cascade with a once-monthly subcutaneous injection.
• Clinical trials, including the VANGUARD trial, demonstrated that Andembry significantly reduced HAE attack rates and achieved attack-free status in a substantial portion of patients.
• The approvals mark a significant advancement in HAE management, providing patients with a convenient, long-term control option, and are based on positive Phase 3 trial results.
NTLA-2002 Shows Promise as Functional Cure for Hereditary Angioedema in Phase 2 Trial
• Phase 2 trial results show NTLA-2002 significantly reduces swelling attacks in hereditary angioedema (HAE) patients, with up to 80% attack reduction at the 50 mg dose.
• A substantial portion of patients receiving NTLA-2002 experienced complete attack-free periods, with some remaining attack-free through the latest assessments.
• NTLA-2002 was generally well-tolerated, with no serious side effects reported, suggesting a favorable safety profile for this gene-editing therapy.
• Intellia Therapeutics has initiated a Phase 3 trial based on these positive results, potentially redefining the treatment paradigm for HAE.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath